CPT code 0059U is a Proprietary Laboratory Analyses (PLA) code for the Merkel Virus VP1 Capsid Antibody assay developed and performed by the University of Washington, Department of Laboratory Medicine. The test identifies antibodies to the polyomavirus capsid protein VP1; a positive finding signals exposure to Merkel cell polyomavirus, which has clinical relevance for epidemiologic assessment and adjunctive evaluation in suspected Merkel cell carcinoma cases, though it does not confirm malignancy. Nationally, PLA codes like 0059U matter because they track unique, manufacturer- or lab-specific diagnostics that are increasingly used in precision infectious disease and oncology testing.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of the code’s clinical purpose, the typical laboratory service setting, and payer coverage landscape. The publication outlines common modifiers associated with laboratory billing, clarifies the test’s diagnostic context and limitations, and summarizes what to expect in claims processing for a proprietary serologic assay. This resource is intended to inform billing staff, laboratory administrators, and policy analysts about the role of CPT code 0059U in clinical workflows and reimbursement discussions. Data not available in the input are noted where applicable.